Novo Nordisk A/S (NVO): Today's Featured Drugs Laggard

Novo Nordisk A/S ( NVO) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Novo Nordisk A/S fell $2.15 (-1.3%) to $158.60 on light volume. Throughout the day, 154,525 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 300,200 shares. The stock ranged in price between $158.17-$160.19 after having opened the day at $159.22 as compared to the previous trading day's close of $160.75. Other companies within the Drugs industry that declined today were: Biota Pharmaceuticals ( BOTA), down 70.1%, Mast Therapeutics ( MSTX), down 38.6%, Oramed Pharmaceuticals ( ORMP), down 13.9% and Cormedix ( CRMD), down 11.6%.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $88.0 billion and is part of the health care sector. Shares are down 1.5% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the positive front, Inovio Pharmaceuticals ( INO), up 24.2%, CytRx Corporation ( CYTR), up 20.9%, Prosensa ( RNA), up 19.6% and Redhill Biopharma ( RDHL), up 18.3% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade